UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated September 1, 2020
(Commission File No. 1-15024)
____________________
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
____________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Form 20-F: ☒
|
|
Form 40-F: ☐
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
|
|
Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
https://twitter.com/novartisnews
|
MEDIA & INVESTOR RELEASE
Novartis
announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
|
·
|
2025 target to increase patients reached in LMICs with strategic innovative
medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across these
initiatives
|
|
·
|
Enhanced target for full carbon neutrality across all company operations and entire supply
chain by 20301
|
|
·
|
New collaboration with the African Union initiated Africa Medical Supplies Platform to aid supply
of Novartis COVID-19 Pandemic Response Portfolio
|
|
·
|
Company completed enrollment in the CAN-COVID Phase III clinical trial with expected readout
in Q4 2020
|
Basel, September 1, 2020 — Novartis will host a virtual investor
event today to provide a comprehensive overview of the company’s progress in its Environmental, Social and Governance (ESG)
strategy.
“ESG is a key strategic priority for the Novartis Board and Executive
Committee and we made progress in all of our key ESG strategic pillars,” said Joerg Reinhardt, Chairman of Novartis.
“Moving forward, we are further reinforcing the way we measure our impact with a set of new ESG targets, increasing our
ambition to drive more value for society.”
Novartis focuses on 4 key strategic ESG pillars defined as material by stakeholders;
Ethical Standards, Pricing and Access, Global Health Challenges and Corporate Citizenship. The company has developed ambitious
and challenging targets against key elements in each of these areas. These include addressing access and global health challenges,
which are areas with the highest unmet need worldwide and where Novartis can have the greatest material ESG impact. Novartis is
also reinforcing its ambition to be a leader in environmental sustainability in the healthcare industry, further strengthening
its already ambitious target for carbon neutrality to include its entire supply chain by 2030.
Vas Narasimhan, CEO of Novartis, said “Novartis continues to take bold
steps to deepen our impact on major global challenges, like access to medicines and climate change. By establishing targets to
measure what matters most for stakeholders, we are further embedding ESG into the core of our business operations and strengthening
our committment to communicating our progress in a transparent way.”
New targets to expand impact on
access to medicines and climate change
As part of the company’s ambition to expand access to innovative medicines
in low- and middle- income countries (LMICs) Novartis is committing to increase patient reach with its strategic
innovative medicines by at least 200% by 2025.
In addition, Novartis plans to increase patient reach of its global health flagship programs in Leprosy, Malaria, Chagas Disease
and Sickle Cell Disease (SCD) by at least 50% over the same time period. Novartis estimates achievement of these targets to result
in a potential reach of over 23 million patients across both initiatives.
Novartis also further strengthened its carbon neutrality target to aim for
full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030, in addition to its already stated target for carbon neutrality
in its own operations by 2025. This new target replaces the previous target aiming for a 50% reduction (vs a 2016 baseline) in
carbon emissions across the supply chain.
Novartis also announced a collaboration with the African Union (55 Member
States which represent all the countries on the African continent) initiated Africa Medical Supplies Platform (AMSP) to support
the supply of medicines from the Novartis COVID-19 Pandemic Response Portfolio. This portfolio of 15 medicines, including Dexamethasone,
for symptomatic treatment of COVID-19 for LMICs was launched in July 2020 and is provided through Sandoz, the generics and biosimilar
division of Novartis. AMSP, a non-profit initiative, provides an online platform that aggregates certified medical equipment,
clinical management devices and medicines to supply African governments in need of critical COVID-19 supplies. This new collaboration
aims to help alleviate supply and logistical constraints by ensuring efficient and rapid access of the COVID-19 Pandemic Response
Portfolio medicines to African governments.
Key highlights on progress in the last 12 months:
Novartis also highlighted the strong progress made in the last 12 months
on a number of key areas, reinforcing ESG as a cornerstone of its strategy.
Access Principles - Novartis launched its Access
Principles2 in 2018 and committed to systematically integrating access strategies in how it researches, develops and
delivers all new medicines. Through Emerging Market Brands (EMBs) and broader access strategies, Novartis reached 376,000 patients
in the first half of 2020. Novartis also established a new business strategy and single organization to broaden patient reach and
availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population
in the world. The newly formed sub-Saharan Africa unit is deploying innovative approaches to sustainably double patient reach across
the full income pyramid by 2022. Adding to partnerships with Clinton Health Access Initiative (CHAI) and AMSP, Novartis SSA unit
is also starting strategic partnerships with different governments to ensure better access to Novartis medicines.
Response to COVID-19
Pandemic - Novartis has made significant contributions to the global effort to combat the COVID-19 pandemic and support the
stability of global healthcare systems. These include leveraging its R&D capabilities, clinical trials expertise, supply of
medicines and philanthropic aid. There are in total over 15 Novartis medicines being studied in 35 investigator-initiated trials
around the world. The company completed enrollment in CAN-COVID Phase III clinical trial, studying canakinumab in patients with
COVID-19 pneumonia, with an expected readout in Q4 2020. Novartis also continues a Phase III clinical trial to evaluate the use
of ruxolitinib in COVID-19 patients with a severe immune reaction. The company has agreed to donate USD 40 million to support
communities around the world impacted by the pandemic. In addition, Novartis continues to be active in cross-industry research
initiatives such as the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and
Mastercard, as well as a COVID-19 directed partnership supported by the Innovative Medicines Initiative (IMI).
Ethical Standards - Continuing
its long term journey to build trust with society, Novartis also resolved its material legacy litigation matters including
the settlements related to Foreign Corrupt Practices Act (FCPA) and US speaker programs. To further reinforce
principles-based thinking and ethical decision-making in the organization and through interactions with external
stakeholders, the new Novartis Code of Ethics which was co-created by thousands of our associates and is embedded in an
innovative decision making framework, launches today, September 1, 2020.
Disclaimer
This press release contains forward-looking
statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements
can generally be identified by words such as “ambitious,” “targets,” “to increase,” “achieve,”
“by 2030,” “by 2025,” “to support,” “expected,” “will,” “strategy,”
“strategic priority,” “moving forward,” “ambition,” “focuses,” “strategic
ESG pillars,” “commitment,” “launched,” “aims” “to expand,” “commiting,”
“plans,” “aim,” “starting,” “committed,” “initiatives,” “long
term journey,” “launches,” “potential,” “can,” “could,” “investigational,”
or similar terms, or by express or implied discussions regarding our environmental, social and governance activities; or regarding
potential new products, potential new indications for existing products, potential product launches, or regarding potential future
revenues from such products; or regarding our response to the COVID-19 pandemic; or regarding research and development activities
and timelines; or regarding current and potential future or pending collaborations, partnerships and alliances; or by discussions
of strategy, plans, expectations or intentions, including with respect to current, planned and potential future efforts in the
areas of ethical standards, pricing and access, global health challenges and responsible citizenship; or regarding efforts to
provide the Novartis Pandemic Response portfolio; or regarding increases in access to medicines and reductions of our energy &
carbon footprint, waste production and water consumption. You should not place undue reliance on these statements. Such forward-looking
statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and
unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee
that we will achieve any or all of the ESG targets described in this press release in the expected time frame, or at all. Neither
can there be any guarantee that the collaborations, partnerships and alliances described in this press release will be successfully
formed, or achieve any or all of their intended goals and objectives in the expected time frame, or at all. Nor can there be any
guarantee that any or all of our efforts to respond to the COVID-19 pandemic will succeed in the expected time frame, or at all.
Neither can there be any guarantee that we will successfully increase access to medicines and health programs as planned, or successfully
reduce our energy and carbon footprint, waste production and water consumption in the expected time frames, or at all. Nor can
there be any guarantee that the investigational or approved products described in this press release will be submitted or approved
for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee
that such products will be commercially successful in the future. In particular, our expectations regarding such efforts, collaborations,
partnerships, alliances and products could be affected by, among other things, the impact of the COVID-19 pandemic on enrollment
in, initiation and completion of our clinical trials in the future, and research and development activities and timelines; the
uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical
data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including
government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency;
our ability to obtain or maintain proprietary intellectual property protection; uncertainties regarding actual or potential legal
proceedings, including, among others, product liability litigation, disputes and litigation with business partners or business
collaborators and intellectual property disputes; our performance on environmental, social and governance measures and our ability
to achieve our environmental, social and governance goals and targets; disruptions of our manufacturing or supply chain impacting
our ability to meet demand for our products in the future; the particular prescribing preferences of physicians and patients;
general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as
COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches,
or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form
20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this
date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result
of new information, future events or otherwise.
About Novartis
Novartis is reimagining medicine to improve
and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to
create transformative treatments in areas of great medical need. In our quest to find new medicines,
we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly
800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people
of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
More information
about the Novartis ESG practices is available at https://www.novartis.com/investors/environmental-social-and-governance.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
References
1.
|
Scope 1 are emissions from sources that are owned or controlled by Novartis, Scope 2 are emissions
from the consumption of purchased energy (e.g. electricity) and Scope 3 are emissions that are a consequence of Novartis operations
(e.g. supply chain, business travel). This commitment goes beyond our existing approved Science Based Targets (March 2019)
|
2.
|
https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles
|
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Antonio Ligi
Novartis External Communications
+41 61 324 1374
antonio.ligi@novartis.com
Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
|
Katrina Lucking
Novartis Global Health & CR Communications
+41 79 484 7625
katrina.lucking@novartis.com
|
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central
|
|
North America
|
|
Samir Shah
|
+41 61 324 7944
|
Sloan Simpson
|
+1 862 778 5052
|
Thomas Hungerbuehler
Isabella Zinck
|
+41 61 324 8425
+41 61 324 7188
|
|
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Novartis AG
|
|
|
|
|
|
|
|
|
|
Date: September 1, 2020
|
By:
|
/s/ PAUL
PENEPENT
|
|
|
Name:
|
Paul Penepent
|
|
|
Title:
|
Head Group Financial Reporting and
Accounting
|
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024